WO2022136502A1 - Hydrogel zur behandlung von druckgeschwüren - Google Patents
Hydrogel zur behandlung von druckgeschwüren Download PDFInfo
- Publication number
- WO2022136502A1 WO2022136502A1 PCT/EP2021/087200 EP2021087200W WO2022136502A1 WO 2022136502 A1 WO2022136502 A1 WO 2022136502A1 EP 2021087200 W EP2021087200 W EP 2021087200W WO 2022136502 A1 WO2022136502 A1 WO 2022136502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogel
- use according
- skin
- weight
- pressure
- Prior art date
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 119
- 208000004210 Pressure Ulcer Diseases 0.000 title claims abstract description 64
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 238000011161 development Methods 0.000 claims description 15
- 230000001681 protective effect Effects 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 229920002635 polyurethane Polymers 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- 238000009423 ventilation Methods 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 229940126601 medicinal product Drugs 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 43
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 206010052428 Wound Diseases 0.000 description 24
- 239000000463 material Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 13
- 239000010410 layer Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 235000010980 cellulose Nutrition 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229920006254 polymer film Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920002396 Polyurea Polymers 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- -1 hydroxybutyl Chemical group 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000005058 Isophorone diisocyanate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100145155 Escherichia phage lambda cIII gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000014306 Trophic disease Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/87—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
- C08L75/04—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
Definitions
- the present invention relates to the use of hydrogel in the treatment of pressure sores and/or the prevention of the development of pressure sores, in particular pressure sores caused by devices or caused by medical devices.
- Decubitus ulcers are generally defined as trophic disorders of tissues, particularly the skin and/or subcutaneous tissue, caused by external pressure exerted over a longer period of time with compression of vessels and local ischemia.
- pressure ulcers can occur when pressure is applied to soft tissues, causing some or all of the blood flow to that tissue to be cut off.
- Shear forces caused by friction on certain skin areas, also contribute significantly to the development of pressure ulcers.
- Such shear forces arise from movement of the skin on surfaces of other materials.
- blood vessels located in these tissues are also compressed, so that the blood flow in these tissues is restricted or interrupted. The decubitus can thus possibly lead to maceration and/or necrosis of the affected tissue or trigger infections.
- the decubitus can be divided into the following stages, whereby these can, for example, merge into one another depending on the duration and/or intensity of the pressure exerted.
- Stage I This is a persistent, circumscribed reddening of the skin that persists even after relief.
- the reddening is sharply defined and may be indurated or overheated.
- the skin is still intact.
- Stage II In this phase, blistering and skin abrasion occur, resulting in partial loss of the skin.
- the epidermis up to parts of the dermis is damaged.
- Stage III In this advanced stage, a loss of all layers of the skin can already be observed. In addition, damage to the subcutaneous tissue and possible necrosis can be observed, which can extend to the underlying muscle tissue. Experience has shown that the necrotic tissue must first be demarcated before the full extent of the tissue damage can be seen. Decubitus III presents clinically as an open, deep ulcer.
- Stage IV At this most critical stage, there is loss of all layers of skin with widespread destruction, tissue necrosis, or damage to muscles, bones, or supporting structures (tendons, joint capsules). Decubitus IV presents clinically as a large, open and deep ulcer.
- stage II, stage III and stage IV pressure sores are known as chronic wounds.
- decubitus ulcers can occur, among other things, when the patient is bedridden, especially on parts of the body where the skin is in direct contact with a bone, but also, for example, under ill-fitting prostheses and plaster casts that are too tight.
- the places where bedsores commonly develop is the skin covering the sacral region, tailbone, heel, or hip bones.
- Other places where decubitus can occur are elbows, knees, joints, shoulders.
- patients whose ability to move is severely restricted are at risk of developing decubitus, since their ability to relieve pressure through independent movement in the parts under pressure is restricted.
- the usual treatment measures for bedridden patients for example, include pressure distribution through frequent changes of position or equipping the bed with pressure-reducing mattresses or pillows.
- decubitus Another special type of decubitus, which can be traced back to the inability to ensure sufficient pressure relief in areas under pressure, is also becoming more and more important.
- These device-related pressure sores (or pressure sores) are considered to be localized damage to the skin and any underlying tissue from pressure exerted by a medical or other device.
- a protective or respiratory mask or goggles during their use there is no possibility of reducing the pressure present under the contact points of the mask on the skin by moving/repositioning the device, which, with prolonged use, leads to education of the described pressure ulcers.
- the present invention according to claim 1 solves at least one of the above problems.
- a hydrogel according to the invention which has a water content of 40% to 90%, enables the treatment of device-related pressure sores and in particular the development of new bedsores or the deterioration of existing bedsores can be effectively prevented. Furthermore, an optimal microclimate for the treatment of pressure sores can be created at the affected area. In addition, it was found that easy handling of the hydrogel used can be guaranteed even after the absorption of water and/or wound fluid, which leads to a high level of acceptance by the patient and/or easy visual inspection of the affected area by the treating person.
- the subject of the present invention is a hydrogel for use in the treatment of pressure sores and/or prevention of the development of pressure sores, the hydrogel having a water content of 40% to 90%.
- the subject matter of the invention is the use of a hydrogel for the treatment of pressure sores and/or the prevention of the development of pressure sores, the hydrogel having a water content of 40% to 90%.
- the invention relates to the use of a hydrogel for the production of a wound dressing for the treatment or prophylaxis of the development of pressure ulcers, the hydrogel having a water content of 40% to 90%.
- Another object of the invention is a kit containing hydrogel and protective or respiratory mask or protective goggles, the hydrogel having a water content of 40% to 90%.
- a decubitus or pressure sore can be defined as above and can arise in the manner also described above.
- a common type of pressure sore can occur when you are bedridden for a long time and is then also referred to as a bed sore.
- the pressure ulcers treated by the hydrogel used according to the invention are device-related pressure ulcers (“device-related pressure ulcers”), in particular device-related pressure ulcers, which fall under stage I or stage II described above fall.
- device-related pressure ulcers can be caused by pressure exerted on the surface of the skin by a medical or other device, causing localized damage to the skin and any underlying tissue.
- the hydrogel used according to the invention can be applied to the skin under the contact points of a ventilation and/or protective mask or protective goggles in order to prevent or at least advantageously reduce the possible formation of device-related pressure sores.
- the pressure sores treated by the hydrogel used according to the invention are pressure sores caused by medicinal products.
- hydrogel designates a finely dispersed system composed of at least one solid and one liquid phase.
- This solid phase forms a spongy, three-dimensional matrix (network) whose pores at least partially filled with a liquid (lyogel), the liquid in the present case being water.
- Both phases preferably penetrate each other completely. By absorbing water, the three-dimensional network can increase its volume through swelling without losing structural cohesion.
- the hydrogel used according to the invention has a water content of 40% to 90%, preferably 50% to 88%, even more preferably 55% to 86%, in particular 60% to 85%.
- the water content of the hydrogel is determined in the manner described in the experimental part.
- a water content is to be understood as meaning the water which can theoretically be released from the hydrogel.
- the hydrogel used according to the invention can advantageously reduce pressure peaks despite its high water content (and consequently a soft consistency).
- the hydrogel used according to the invention can have a water release capacity. In other words, this means that the hydrogel used according to the invention can release moisture, in particular water, to the area to be treated.
- the hydrogel used according to the invention can contain from 3 to 20 mg of moisture per square centimeter (cm 2 ), preferably from 5 to 15 mg of moisture per square centimeter (cm 2 ), in particular from 8 to 12 mg of moisture per square centimeter (cm 2 ), Dispense within 24 hours as measured by TM 0000232.
- the liquid is preferably water.
- the hydrogel used according to the invention can contain 8 mg moisture per square centimeter (cm 2 ), 8.5 mg moisture per square centimeter (cm 2 ), 9.0 mg moisture per square centimeter (cm 2 ), 9.5 mg moisture per square centimeter (cm 2 ), 10.0 mg moisture per square centimeter (cm 2 ), 10.5 mg moisture per square centimeter (cm 2 ), 11.0 mg moisture per square centimeter (cm 2 ), 11.5 mg moisture per square centimeter (cm 2 ), or 12 mg moisture per square centimeter (cm 2 ) within 24 give hours.
- the water releasing ability of the hydrogel is determined in the manner described in the experimental part.
- the water content and/or the water release capacity of the hydrogel used according to the invention in addition to being comfortable to wear, enables gentle treatment of skin areas affected by device-related pressure ulcers through the optimal supply of moisture.
- the hydrogel used according to the invention can preferably absorb substances released from the wound, in particular wound exudate, as a result of which renewed contact with the wound (recontamination) can be prevented or at least advantageously reduced.
- the hydrogel used according to the invention has an absorption capacity of 1 to 10 g/g (hydrogel), preferably 1.1 to 5 g/g (hydrogel), even more preferably 1.2 to 3 g/g (hydrogel ) within 24 hours.
- the absorption capacity of the hydrogel is determined in the manner described in the experimental part.
- the hydrogel used according to the invention has a pH of from 5 to 9, preferably from 6.7 to 8.7, more preferably from 7.2 to 8.2, even more preferably from 7.5 to 7.9 , specifically from 7.7 to .
- the pH is determined in the manner described in the experimental part.
- the hydrogel used according to the invention can, in an alternative embodiment, also contain appropriate buffer substances or contain a buffer solution with the appropriately adjusted pH.
- a non-limiting example of a buffer solution would be 0.1 molar sodium phosphate solution (pH 7.4). It has been found that an advantageous treatment of pressure sores and/or the prophylaxis of the development of pressure sores can be made possible by the aforementioned pH value range.
- the matrix of the hydrogel used according to the invention can preferably be composed of a synthetic or natural material, more preferably of a synthetic or natural polymer material.
- natural polymers that can be used as a matrix for the hydrogel used according to the invention are agar, alginic acid and its salts and derivatives, guar gum, chitin and its derivatives, chitosan (derivatives), carrageenan, xanthan, gum arabic, tragacanth, gellan , pectin and mixtures thereof.
- These polymers can also be viewed as plant polymeric material for the formation of hydrogels. Further examples are gelatin, peptin and glycoproteins and mixtures thereof. These polymers can also be viewed as animal polymeric material.
- cellulose and/or derivatives thereof can also be used as the matrix for the hydrogel used according to the invention.
- the group of cellulose derivatives includes, in particular, cellulose ethers and cellulose esters and their salts.
- the cellulose ethers used here are preferably hydroxyalkyl celluloses, in particular hydroxy-C1-6-alkyl cellulose such as, for example, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose or hydroxybutyl cellulose and very particularly preferably hydroxymethyl cellulose or hydroxyethyl cellulose.
- the cellulose ester used is in particular carboxyalkyl cellulose, in particular carboxy-C1-6-alkyl cellulose such as carboxymethyl cellulose, carboxyethyl cellulose, carboxypropyl cellulose or carboxybutyl cellulose or salts thereof and very particularly preferably carboxymethyl cellulose or carboxyethyl cellulose or salts thereof, in particular sodium salts. Furthermore, mixtures thereof can be used.
- the number average molecular weight of the celluloses and/or their derivatives is preferably 1000-250000 g/mol, more preferably 5000-175000 g/mol, in particular 10000-100000 g/mol. The number average molecular weight is preferably determined using gel permeation chromatography.
- the matrix of the hydrogel used according to the invention can also be a synthetic polymer.
- the synthetic polymer generally has a number average molecular weight of 2500 to 25,000,000 g/mol, preferably 5,000 to 5,000,000 g/mol. more preferably from 50,000 to 1,000,000 g/mol.
- Examples of synthetic polymers are polyurethane, polyvinyl alcohol, poly(meth)acrylate and polyvinylpyrrolidone.
- the hydrogel used according to the invention can be a polyurethane-based hydrogel.
- the matrix of the hydrogel used according to the invention is based on a polyurethane.
- Hydrogel matrices comprising a polyurethane-polyurea copolymer are particularly suitable in the context of the present invention.
- This polyurethane-polyurea copolymer can be formed in particular from a prepolymer with aliphatic diisocyanate groups and a polyamine based on polyethylene oxide.
- the polyurethane-polyurea copolymer can be formed from a prepolymer with isophorone diisocyanate ends, a polyamine based on polyethylene oxide and water.
- the hydrogel used according to the invention can also comprise at least one polyhydric alcohol from the group of dihydric, trihydric, tetrahydric, pentahydric or hexahydric alcohols.
- the alcohol can be chosen from the group of glycols, in particular ethylene glycol or propylene glycol, and also sorbitol or glycerol or mixtures thereof. These alcohols are excellent moisturizers.
- the hydrogel according to the invention can comprise 0 to 50% by weight of a polyhydric alcohol, more preferably 5 to 40% by weight of a polyhydric alcohol and very particularly preferably 10 to 30% by weight of a polyhydric alcohol.
- the hydrogel used according to the invention comprises in particular at least one salt.
- the hydrogel matrix comprises an inorganic salt. Chlorides, iodides, sulfates, hydrogen sulfates, carbonates, hydrogen carbonates, phosphates, dihydrogen phosphates or hydrogen phosphates of the alkali and alkaline earth metals are particularly suitable in this connection.
- the hydrogel matrix comprises sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or mixtures thereof. This Salts do a particularly good job of simulating the electrolyte mixture in a wound serum discharged from a wound.
- the hydrogel used according to the invention and comprising these salts thus provides a wound with a climate that particularly promotes wound healing. It can be provided that the hydrogel used according to the invention comprises 0 to 5% by weight, preferably 0.1 to 3% by weight, very particularly preferably 0.5 to 1.5% by weight of at least one salt.
- the hydrogel used according to the invention is formed from 6 to 30% by weight of a prepolymer with aliphatic diisocyanate groups, 4 to 20% by weight of diamine based on polyethylene oxide, 5 to 30% by weight of a polyhydric alcohol selected from from the group consisting of propylene glycol and/or glycerin, 0.5 - 1.5% by weight of a salt selected from the group sodium chloride, potassium chloride, magnesium chloride, calcium chloride or mixtures thereof and 40% by weight to 80% by weight Water .
- the hydrogel used in the present invention is composed of 6 to 20% by weight, formed from in particular about 12.6% by weight isophorone diisocyanate terminated prepolymer, 4 to 15% by weight, in particular about 8.7% by weight diamine polyethylene oxide base, 15 to 20 wt%, especially about 16.5 wt%/or glycerin, 0.5 to 1.5 wt%, especially about 1.0 wt% of a salt, preferably sodium chloride, and 50 wt% -% to 80% by weight, in particular about 61.3% by weight, water.
- a salt preferably sodium chloride
- the present invention relates to the use of a hydrogel for producing a wound dressing for treating pressure sores and/or preventing the development of pressure sores, the hydrogel having a water content of 40% to 90%.
- the wound dressing produced using the hydrogel is preferably used in the treatment of device-related pressure ulcers and the hydrogel has a water content of 40% to 90%, preferably 60% to 85%.
- the hydrogel used to produce a wound dressing can preferably be fixed to the affected area of the skin. This can be done solely by the contact pressure of the device, for example protective goggles, on the wound dressing produced using the hydrogel, which is arranged between the affected area of the skin and the device itself.
- the hydrogel used to make a dressing may be fixed to the skin at the site of interest using a fixative such as an adhesive.
- a fixative such as an adhesive
- the edge area of a layer that overlaps the hydrogel and is arranged on the side facing away from the skin can be provided with a fixing agent such as an adhesive, so that the hydrogel can be applied and fixed directly to the affected area of the skin.
- Suitable fixatives such as medically acceptable adhesives are known to those skilled in the art.
- the wound dressing can preferably be available as a variant with a frame (“island bandage”).
- the hydrogel used has a thickness of 0.5 to 2.0 mm, preferably 0.6 to 1.8 mm, in particular 1.0 to 1.6 mm. This thickness makes it possible to achieve both a comfortable fit and sufficient prevention of pressure peaks through the device on the skin, so that the formation of a pressure sore can be advantageously prevented.
- the wound dressing can preferably be present as a variant without a frame.
- the hydrogel used has a thickness of 1.0 to 2.0 mm, preferably 1.1 to 1.8 mm, in particular 1.2 to 1.6 mm. This thickness makes it possible to achieve both a comfortable fit and sufficient prevention of pressure peaks through the device on the skin, so that the formation of a pressure sore can be advantageously prevented.
- the hydrogel used to produce a wound dressing is preferably transparent.
- transparency is one sufficient transmittance of light in the visible spectrum of a material, in this case hydrogel.
- the side of the material facing away from the viewer's eye can be viewed through the material.
- the condition of the skin area lying under the hydrogel can be viewed visually and then assessed without the wound dressing produced using the hydrogel having to be removed from the relevant skin area.
- the transparency is thus preferably determined by a visual check. In this way, for example, unnecessary changing of the wound dressing can be avoided, which firstly saves the patient the resulting pain and secondly avoids an unnecessarily high cost of materials.
- the wound dressing produced using the hydrogel preferably comprises a cover layer which is attached to the side of the hydrogel facing away from the skin.
- Films or foams made from polyurethane, polyester, polyether urethane, polyester urethane, polyether-polyamide copolymers, polyacrylate or polymethacrylate are preferably suitable as the top layer.
- a water-impermeable and water vapor-permeable polymer film is suitable as the cover layer.
- a polyurethane film, polyester urethane film or polyether urethane film is preferred.
- the topsheet preferably has a moisture vapor transmission rate (MVTR) of from 250 g/m 2 /24 hours to 1000 g/m 2 /24 hours, more preferably from 300 g/m 2 /24 hours to 750 g/m 2 /24 hours (measured according to DIN EN 13726-2:2002, upright).
- MVTR moisture vapor transmission rate
- the water vapor permeability of the top layer, in particular of the polymer film, is alternatively preferably at least 300 g/m 2 /24 hours, in particular at least 1000 g/m 2 /24 hours and very particularly preferably at least 2000 g/m 2 /24 hours to eg 5000 g/m 2 /24 hours or 10,000 g/m 2 /24 hours (measured according to DIN EN 13726-2:2002, upright).
- the cover layer can be covered with an adhesive layer.
- the cover layer has a moisture-proof, adhesive edge section. This edge section ensures that the hydrogel can be applied and fixed to the relevant skin areas.
- a further object of the invention is a kit which contains hydrogel and a protective or ventilation mask or goggles, the hydrogel having a water content of 40% to 90%.
- the hydrogel contained in the kit is preferably in the form of a layered structure.
- a preferably sterile cutting device such as a scalpel or scissors
- the individually required dimensions of the hydrogel for the relevant skin areas of the patient can then be cut, applied and, if necessary, fixed before the protective or ventilation mask or protective goggles are put on.
- the kit according to the invention contains a cutting device, in particular scissors.
- FIG. 1 shows a diagram in which the results of the FEM (finite element method) of the hydrogel used according to the invention are shown.
- the abscissa shows von Mises stresses occurring on the skin.
- the ordinate shows the proportion of the relevant comparison volume (volume of interest, VOI) that has von Mises stresses that are at least as large as the associated abscissa sections.
- the water content um is calculated as follows: 100
- filter paper sheets with a diameter of 5.5 centimeters are conditioned in air at 23° C. and 50 ⁇ 4% relative humidity for 24 hours.
- the water resistance is calculated as follows:
- the adsorption capacity WA is calculated as follows:
- a hydrogel used according to the invention can be produced by mixing (reacting) a mixture of components 1) to 4) with component 5) and then transferring to a mold to obtain the desired thickness.
- Isocyanide e.g. Aquapol PI-1300-31 12.58% by weight
- the FEM is a general and computer-aided numerical method used for various physical tasks. Logically, the FEM is based on the numerical solution of a complex system of differential equations. FEM breaks down large problems into a multitude of smaller parts called finite elements. The analysis is carried out with each of these elements and, taken as a whole, results in a solution for the entire problem.
- MRI scans of a test subject served as the basis for the pelvic model in order to ensure the greatest possible anatomical accuracy of the model.
- the FE models include 3,900,000 nodes.
- Soft tissues were represented as non-linear materials, with muscle grouped into one material, and fat and skin each grouped as compressible materials.
- the bones were gathered as one rigid body.
- the modeling was based on the following material properties:
- a relevant model volume (volume of interest, VOI) with dimensions of 6.7 cm x 2.0 cm x 5.1 cm (x-direction x y-direction x z-direction) was formed, which included the sacrum (os sacrum) and surrounding soft tissue including skin.
- Von Mises stress designates a fictitious uniaxial stress which, based on a certain material-mechanical or mathematical criterion, represents a material stress that is hypothetically equivalent to a real, multi-axial stress state. Based on the Von Mises stress, the real, generally three-dimensional state of stress in the component in the strength or yield condition can be compared with the characteristic values from the uniaxial tensile test (material characteristic values, e.g. yield point or tensile strength).
- the von Mises stresses can be calculated using the following formula:
- ol, oll, and cIII are the principal stresses occurring in the three spatial directions.
- the 10% value is of significant interest. This value indicates which maximum stresses occur in a maximum of 10% of the relevant comparison volume. It corresponds to the curve point that belongs to the ordinate section at 10% VOI.
- the suitability for preventing the development of pressure sores such as device-related pressure sores can be postulated, provided that the 10% value for the stresses that occur is a reduction of more than 10% learns.
- Curve (A) hydrogel according to the invention in parallel: 19.0 kPa
- Curve (B) hydrogel according to the invention vertical: 20.0 kPa
- the 10% value for the occurring von Mises stresses on the skin in the relevant model volume could be reduced by more than 20% by using a hydrogel used according to the invention
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Materials For Medical Uses (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021405613A AU2021405613A1 (en) | 2020-12-23 | 2021-12-22 | Hydrogel for treating pressure ulcers |
US18/269,233 US20240226366A9 (en) | 2020-12-23 | 2021-12-22 | Hydrogel for treating pressure ulcers |
EP21840970.4A EP4267081A1 (de) | 2020-12-23 | 2021-12-22 | Hydrogel zur behandlung von druckgeschwüren |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020134827.4 | 2020-12-23 | ||
DE102020134827.4A DE102020134827A1 (de) | 2020-12-23 | 2020-12-23 | Hydrogel zur Behandlung von Druckgeschwüren |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022136502A1 true WO2022136502A1 (de) | 2022-06-30 |
Family
ID=79425759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/087200 WO2022136502A1 (de) | 2020-12-23 | 2021-12-22 | Hydrogel zur behandlung von druckgeschwüren |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240226366A9 (de) |
EP (1) | EP4267081A1 (de) |
AU (1) | AU2021405613A1 (de) |
DE (1) | DE102020134827A1 (de) |
WO (1) | WO2022136502A1 (de) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424787A (en) * | 1994-06-20 | 1995-06-13 | Zegarelli; Peter J. | Eyeglasses with mask support attachment means |
DE102005035879A1 (de) * | 2005-07-30 | 2007-02-01 | Paul Hartmann Ag | Hydrogel |
DE102008031183A1 (de) * | 2008-07-03 | 2010-01-07 | Paul Hartmann Ag | Wundauflage |
EP2246073A1 (de) * | 2008-02-25 | 2010-11-03 | Teikoku Seiyaku Co., Ltd. | Wundabdeckungs-hydrogelmaterial |
DE102011106046A1 (de) * | 2011-06-30 | 2013-01-03 | Paul Hartmann Ag | Wundversorgungsprodukt |
EP3266472A1 (de) * | 2016-07-08 | 2018-01-10 | Mölnlycke Health Care AB | Medizinischer verband mit einem träger und einem verbundstoffmaterial |
WO2018115453A1 (de) * | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige hydrogelzusammensetzung, umfassend elementare silberpartikel |
WO2018115257A1 (de) * | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige hydrogele zur wundversorgung |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6082360A (en) | 1995-05-04 | 2000-07-04 | Hans Rudolph, Inc. | Mask with gel seal |
DE202005012015U1 (de) | 2005-07-30 | 2006-12-14 | Paul Hartmann Ag | Hydrogel |
EP1894549A1 (de) | 2006-08-29 | 2008-03-05 | Helle Kayerod | Schützende Gesichtsmaske |
-
2020
- 2020-12-23 DE DE102020134827.4A patent/DE102020134827A1/de active Pending
-
2021
- 2021-12-22 EP EP21840970.4A patent/EP4267081A1/de active Pending
- 2021-12-22 US US18/269,233 patent/US20240226366A9/en active Pending
- 2021-12-22 WO PCT/EP2021/087200 patent/WO2022136502A1/de active Application Filing
- 2021-12-22 AU AU2021405613A patent/AU2021405613A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424787A (en) * | 1994-06-20 | 1995-06-13 | Zegarelli; Peter J. | Eyeglasses with mask support attachment means |
DE102005035879A1 (de) * | 2005-07-30 | 2007-02-01 | Paul Hartmann Ag | Hydrogel |
EP2246073A1 (de) * | 2008-02-25 | 2010-11-03 | Teikoku Seiyaku Co., Ltd. | Wundabdeckungs-hydrogelmaterial |
DE102008031183A1 (de) * | 2008-07-03 | 2010-01-07 | Paul Hartmann Ag | Wundauflage |
DE102011106046A1 (de) * | 2011-06-30 | 2013-01-03 | Paul Hartmann Ag | Wundversorgungsprodukt |
EP3266472A1 (de) * | 2016-07-08 | 2018-01-10 | Mölnlycke Health Care AB | Medizinischer verband mit einem träger und einem verbundstoffmaterial |
WO2018115453A1 (de) * | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige hydrogelzusammensetzung, umfassend elementare silberpartikel |
WO2018115257A1 (de) * | 2016-12-23 | 2018-06-28 | Paul Hartmann Ag | Wasserhaltige hydrogele zur wundversorgung |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF WOUND CARE, vol. 29, no. 2, February 2020 (2020-02-01) |
LEVY ASCHWARTZ DGEFEN A: "The contribution of a directional preference of stiffness to the efficacy of prophylactic sacral dressings in protecting healthy and diabetic tissues from pressure injury: computational modelling studies", INT.WOUND J, 2017 |
Also Published As
Publication number | Publication date |
---|---|
AU2021405613A1 (en) | 2023-07-06 |
US20240226366A9 (en) | 2024-07-11 |
EP4267081A1 (de) | 2023-11-01 |
US20240131216A1 (en) | 2024-04-25 |
DE102020134827A1 (de) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2309956B1 (de) | Wundauflage und verfahren zu ihrer herstellung | |
EP2338529B1 (de) | Hydrogelmatrix mit verbesserten Klebeeigenschaften | |
EP2310057B1 (de) | Wundauflage mit hydrogelmatrix | |
EP2726113B1 (de) | Wundversorgungsprodukt | |
EP1962801B1 (de) | Medizinische zusammensetzung und wundkontaktschicht mit einer zusammensetzung | |
EP3033116B1 (de) | Wundpflegeartikel aufweisend superabsorbierende fasern und superabsorbierende partikel | |
EP2338528B1 (de) | Hydrogelmatrix mit erhöhter Absorptionskapazität für Flüssigkeiten | |
EP3558400B1 (de) | Wasserhaltige hydrogele zur wundversorgung | |
DE102005035879A1 (de) | Hydrogel | |
EP2717815A1 (de) | Wundauflage, enthaltend schaumstoff und salbengrundlage und quellstoff, zur unterdrucktherapie | |
DE60215347T2 (de) | Wundverband | |
DE60309425T2 (de) | Alginatgewebe und Superabsorbens enthaltendes Wundpflaster | |
DE69708141T2 (de) | Wundverbände und verfahren zu ihrer herstellung | |
WO2022136502A1 (de) | Hydrogel zur behandlung von druckgeschwüren | |
DE202023100113U1 (de) | Dreidimensional vernetztes Hydrogel | |
DE69413048T2 (de) | Alginatwundverbände | |
DE69720072T2 (de) | Verbandsgewebe mit verlängerter therapeutischer wirkung | |
WO2021123028A1 (de) | Medizinischer artikel zur prophylaxe von dekubitalulcera | |
DE102010023239A1 (de) | Absorptionskörper zur Verwendung als Liegeunterlage | |
DE202005012015U1 (de) | Hydrogel | |
EP3838301A1 (de) | Verfahren zur herstellung eines cellulosederivathaltigen polymers für medizinische zwecke, insbesondere für die wundbehandlung | |
DE102012201463A1 (de) | In der Permeabilität variierbare Membranschicht auf Basis von Carrageen oder Chitosan als Wundauflage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21840970 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18269233 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2021405613 Country of ref document: AU Date of ref document: 20211222 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021840970 Country of ref document: EP Effective date: 20230724 |